DNASE1L3 as a Prognostic Biomarker Associated with Immune Cell Infiltration in Cancer
Deoxyribonuclease 1 like 3 (DNASE1L3) is critically involved in apoptosis and immune response, however, its role in cancer has yet to be deciphered. We aimed to explore the prognostic value of DNASE1L3 across a series of malignancies. Based on Oncomine database and Tumor Immune Estimation Resource (...
Gespeichert in:
| Veröffentlicht in: | OncoTargets and therapy 2021-01, Vol.14, p.2003-2017 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2017 |
|---|---|
| container_issue | |
| container_start_page | 2003 |
| container_title | OncoTargets and therapy |
| container_volume | 14 |
| creator | Deng, Zenghua Xiao, Mengmeng Du, Dexiao Luo, Nan Liu, Dongfang Liu, Tingting Lian, Dongbo Peng, Jirun |
| description | Deoxyribonuclease 1 like 3 (DNASE1L3) is critically involved in apoptosis and immune response, however, its role in cancer has yet to be deciphered. We aimed to explore the prognostic value of DNASE1L3 across a series of malignancies.
Based on Oncomine database and Tumor Immune Estimation Resource (TIMER), expression profiling of DNASE1L3 was detailed in malignancies. Using PrognoScan, Kaplan-Meier Plotter, GEPIA2, and bc-GenEcMiner v4.5, prognostic value of DNASE1L3 was estimated in diverse cancers. Based on TIMER, association between DNASEL13 expression and immune infiltration was examined in various cancers. Then, mRNA level of DNASE1L3 in hepatocellular carcinoma (HCC) samples (n=22) and stomach adenocarcinoma (STAD) samples (n=17) was measured with qRT-PCR. Immunohistochemistry was performed to confirm expression of DNASE1L3 in paraffin-embedded tissues of HCC (n=9) and lung adenocarcinoma (n=20).
DNASE1L3 was downregulated in multiple cancers, including breast invasive carcinoma (BRCA), cholangiocarcinoma (CHOL), liver hepatocellular carcinoma (LIHC), and lung adenocarcinoma (LUAD). A lower level of DNASE1L3 correlated with poorer prognosis in various cancers, especially in breast, liver, kidney, stomach, lung adenocarcinoma and sarcoma (SARC). Moreover, DNASE1L3 was positively related to immune cell infiltration in many cancers, including BRCA, LIHC, STAD, LUAD, and SARC. DNASE1L3 was significantly associated with CCR7/CCL19 in cancers. DNASE1L3 was downregulated in HCC and STAD tissues as demonstrated by qRT-PCR, as well as in HCC and LUAD samples, as shown by immunohistochemistry.
DNASE1L3 has potential to serve as a prognostic biomarker in cancer of the breast, kidney, liver, stomach, lung adenocarcinoma and sarcoma. Down-regulation of DNASE1L3 may participate in immune escape via CCR7/CCL19 axis. |
| doi_str_mv | 10.2147/OTT.S294332 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7987320</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A669417984</galeid><sourcerecordid>A669417984</sourcerecordid><originalsourceid>FETCH-LOGICAL-c549t-1ca3847bcc91314d4a4c09ebc6a7a0d19a57b03a42e98592ed57fc86fdcb7aa33</originalsourceid><addsrcrecordid>eNptkt1rFDEUxQdRbK0--S4BQQTZNV-TTF4K61rtwmKFbp_DnUxmN3UmqcmMpf-9Wbu2uyJ5SCC_e-69h1MUrwmeUsLlx4vVanpJFWeMPimOCZHVRCiGn-69j4oXKV1jLERF-fPiiDEpBS_xcXH1-dvs8owsGYKEAH2PYe1DGpxBn1zoIf6wEc1SCsbBYBt064YNWvT96C2a265DC9-6bogwuOCR82gO3tj4snjWQpfsq919Ulx9OVvNzyfLi6-L-Ww5MSVXw4QYYBWXtTGKMMIbDtxgZWsjQAJuiIJS1pgBp1ZVpaK2KWVrKtE2ppYAjJ0Up_e6N2Pd28ZYn0fp9E10efQ7HcDpwx_vNnodfmmpKskozgLvdwIx_BxtGnTvksmLgbdhTJqWWJSE8j_o23_Q6zBGn9fLFGFlJQSnj9QaOqudb0Pua7aieiaE4iR35pma_ofKp7G9M8HbbKo9LHi3V7Cx0A2bFLpxa3s6BD_cgyaGlKJtH8wgWG_jonNc9C4umX6z798D-zcf7Dfn0bg1</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2513586642</pqid></control><display><type>article</type><title>DNASE1L3 as a Prognostic Biomarker Associated with Immune Cell Infiltration in Cancer</title><source>DOVE Medical Press Journals</source><source>Taylor & Francis Open Access(OpenAccess)</source><source>PubMed Central</source><source>EZB Electronic Journals Library</source><source>PubMed Central Open Access</source><creator>Deng, Zenghua ; Xiao, Mengmeng ; Du, Dexiao ; Luo, Nan ; Liu, Dongfang ; Liu, Tingting ; Lian, Dongbo ; Peng, Jirun</creator><creatorcontrib>Deng, Zenghua ; Xiao, Mengmeng ; Du, Dexiao ; Luo, Nan ; Liu, Dongfang ; Liu, Tingting ; Lian, Dongbo ; Peng, Jirun</creatorcontrib><description>Deoxyribonuclease 1 like 3 (DNASE1L3) is critically involved in apoptosis and immune response, however, its role in cancer has yet to be deciphered. We aimed to explore the prognostic value of DNASE1L3 across a series of malignancies.
Based on Oncomine database and Tumor Immune Estimation Resource (TIMER), expression profiling of DNASE1L3 was detailed in malignancies. Using PrognoScan, Kaplan-Meier Plotter, GEPIA2, and bc-GenEcMiner v4.5, prognostic value of DNASE1L3 was estimated in diverse cancers. Based on TIMER, association between DNASEL13 expression and immune infiltration was examined in various cancers. Then, mRNA level of DNASE1L3 in hepatocellular carcinoma (HCC) samples (n=22) and stomach adenocarcinoma (STAD) samples (n=17) was measured with qRT-PCR. Immunohistochemistry was performed to confirm expression of DNASE1L3 in paraffin-embedded tissues of HCC (n=9) and lung adenocarcinoma (n=20).
DNASE1L3 was downregulated in multiple cancers, including breast invasive carcinoma (BRCA), cholangiocarcinoma (CHOL), liver hepatocellular carcinoma (LIHC), and lung adenocarcinoma (LUAD). A lower level of DNASE1L3 correlated with poorer prognosis in various cancers, especially in breast, liver, kidney, stomach, lung adenocarcinoma and sarcoma (SARC). Moreover, DNASE1L3 was positively related to immune cell infiltration in many cancers, including BRCA, LIHC, STAD, LUAD, and SARC. DNASE1L3 was significantly associated with CCR7/CCL19 in cancers. DNASE1L3 was downregulated in HCC and STAD tissues as demonstrated by qRT-PCR, as well as in HCC and LUAD samples, as shown by immunohistochemistry.
DNASE1L3 has potential to serve as a prognostic biomarker in cancer of the breast, kidney, liver, stomach, lung adenocarcinoma and sarcoma. Down-regulation of DNASE1L3 may participate in immune escape via CCR7/CCL19 axis.</description><identifier>ISSN: 1178-6930</identifier><identifier>EISSN: 1178-6930</identifier><identifier>DOI: 10.2147/OTT.S294332</identifier><identifier>PMID: 33776450</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Adenocarcinoma ; Apoptosis ; Biomarkers ; Breast cancer ; CCL19 protein ; CCR7 protein ; Cholangiocarcinoma ; Deoxyribonuclease ; Esophagus ; Gene expression ; Head & neck cancer ; Hepatocellular carcinoma ; Immune response ; Immune system ; Immunohistochemistry ; Immunotherapy ; Infiltration ; Invasiveness ; Kidneys ; Leukemia ; Liver ; Liver cancer ; Lung cancer ; Lung carcinoma ; Lymphoma ; Medical prognosis ; Melanoma ; Mesothelioma ; Metastases ; mRNA ; Neutrophils ; Original Research ; Ovarian cancer ; Paraffin ; Prognosis ; Prostate ; RNA ; Sarcoma ; Signal transduction ; Skin cancer ; Software ; Stomach ; Thyroid cancer ; Tumors</subject><ispartof>OncoTargets and therapy, 2021-01, Vol.14, p.2003-2017</ispartof><rights>2021 Deng et al.</rights><rights>COPYRIGHT 2021 Dove Medical Press Limited</rights><rights>2021. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Deng et al. 2021 Deng et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c549t-1ca3847bcc91314d4a4c09ebc6a7a0d19a57b03a42e98592ed57fc86fdcb7aa33</citedby><cites>FETCH-LOGICAL-c549t-1ca3847bcc91314d4a4c09ebc6a7a0d19a57b03a42e98592ed57fc86fdcb7aa33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987320/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987320/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3862,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33776450$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Deng, Zenghua</creatorcontrib><creatorcontrib>Xiao, Mengmeng</creatorcontrib><creatorcontrib>Du, Dexiao</creatorcontrib><creatorcontrib>Luo, Nan</creatorcontrib><creatorcontrib>Liu, Dongfang</creatorcontrib><creatorcontrib>Liu, Tingting</creatorcontrib><creatorcontrib>Lian, Dongbo</creatorcontrib><creatorcontrib>Peng, Jirun</creatorcontrib><title>DNASE1L3 as a Prognostic Biomarker Associated with Immune Cell Infiltration in Cancer</title><title>OncoTargets and therapy</title><addtitle>Onco Targets Ther</addtitle><description>Deoxyribonuclease 1 like 3 (DNASE1L3) is critically involved in apoptosis and immune response, however, its role in cancer has yet to be deciphered. We aimed to explore the prognostic value of DNASE1L3 across a series of malignancies.
Based on Oncomine database and Tumor Immune Estimation Resource (TIMER), expression profiling of DNASE1L3 was detailed in malignancies. Using PrognoScan, Kaplan-Meier Plotter, GEPIA2, and bc-GenEcMiner v4.5, prognostic value of DNASE1L3 was estimated in diverse cancers. Based on TIMER, association between DNASEL13 expression and immune infiltration was examined in various cancers. Then, mRNA level of DNASE1L3 in hepatocellular carcinoma (HCC) samples (n=22) and stomach adenocarcinoma (STAD) samples (n=17) was measured with qRT-PCR. Immunohistochemistry was performed to confirm expression of DNASE1L3 in paraffin-embedded tissues of HCC (n=9) and lung adenocarcinoma (n=20).
DNASE1L3 was downregulated in multiple cancers, including breast invasive carcinoma (BRCA), cholangiocarcinoma (CHOL), liver hepatocellular carcinoma (LIHC), and lung adenocarcinoma (LUAD). A lower level of DNASE1L3 correlated with poorer prognosis in various cancers, especially in breast, liver, kidney, stomach, lung adenocarcinoma and sarcoma (SARC). Moreover, DNASE1L3 was positively related to immune cell infiltration in many cancers, including BRCA, LIHC, STAD, LUAD, and SARC. DNASE1L3 was significantly associated with CCR7/CCL19 in cancers. DNASE1L3 was downregulated in HCC and STAD tissues as demonstrated by qRT-PCR, as well as in HCC and LUAD samples, as shown by immunohistochemistry.
DNASE1L3 has potential to serve as a prognostic biomarker in cancer of the breast, kidney, liver, stomach, lung adenocarcinoma and sarcoma. Down-regulation of DNASE1L3 may participate in immune escape via CCR7/CCL19 axis.</description><subject>Adenocarcinoma</subject><subject>Apoptosis</subject><subject>Biomarkers</subject><subject>Breast cancer</subject><subject>CCL19 protein</subject><subject>CCR7 protein</subject><subject>Cholangiocarcinoma</subject><subject>Deoxyribonuclease</subject><subject>Esophagus</subject><subject>Gene expression</subject><subject>Head & neck cancer</subject><subject>Hepatocellular carcinoma</subject><subject>Immune response</subject><subject>Immune system</subject><subject>Immunohistochemistry</subject><subject>Immunotherapy</subject><subject>Infiltration</subject><subject>Invasiveness</subject><subject>Kidneys</subject><subject>Leukemia</subject><subject>Liver</subject><subject>Liver cancer</subject><subject>Lung cancer</subject><subject>Lung carcinoma</subject><subject>Lymphoma</subject><subject>Medical prognosis</subject><subject>Melanoma</subject><subject>Mesothelioma</subject><subject>Metastases</subject><subject>mRNA</subject><subject>Neutrophils</subject><subject>Original Research</subject><subject>Ovarian cancer</subject><subject>Paraffin</subject><subject>Prognosis</subject><subject>Prostate</subject><subject>RNA</subject><subject>Sarcoma</subject><subject>Signal transduction</subject><subject>Skin cancer</subject><subject>Software</subject><subject>Stomach</subject><subject>Thyroid cancer</subject><subject>Tumors</subject><issn>1178-6930</issn><issn>1178-6930</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkt1rFDEUxQdRbK0--S4BQQTZNV-TTF4K61rtwmKFbp_DnUxmN3UmqcmMpf-9Wbu2uyJ5SCC_e-69h1MUrwmeUsLlx4vVanpJFWeMPimOCZHVRCiGn-69j4oXKV1jLERF-fPiiDEpBS_xcXH1-dvs8owsGYKEAH2PYe1DGpxBn1zoIf6wEc1SCsbBYBt064YNWvT96C2a265DC9-6bogwuOCR82gO3tj4snjWQpfsq919Ulx9OVvNzyfLi6-L-Ww5MSVXw4QYYBWXtTGKMMIbDtxgZWsjQAJuiIJS1pgBp1ZVpaK2KWVrKtE2ppYAjJ0Up_e6N2Pd28ZYn0fp9E10efQ7HcDpwx_vNnodfmmpKskozgLvdwIx_BxtGnTvksmLgbdhTJqWWJSE8j_o23_Q6zBGn9fLFGFlJQSnj9QaOqudb0Pua7aieiaE4iR35pma_ofKp7G9M8HbbKo9LHi3V7Cx0A2bFLpxa3s6BD_cgyaGlKJtH8wgWG_jonNc9C4umX6z798D-zcf7Dfn0bg1</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Deng, Zenghua</creator><creator>Xiao, Mengmeng</creator><creator>Du, Dexiao</creator><creator>Luo, Nan</creator><creator>Liu, Dongfang</creator><creator>Liu, Tingting</creator><creator>Lian, Dongbo</creator><creator>Peng, Jirun</creator><general>Dove Medical Press Limited</general><general>Taylor & Francis Ltd</general><general>Dove</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210101</creationdate><title>DNASE1L3 as a Prognostic Biomarker Associated with Immune Cell Infiltration in Cancer</title><author>Deng, Zenghua ; Xiao, Mengmeng ; Du, Dexiao ; Luo, Nan ; Liu, Dongfang ; Liu, Tingting ; Lian, Dongbo ; Peng, Jirun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c549t-1ca3847bcc91314d4a4c09ebc6a7a0d19a57b03a42e98592ed57fc86fdcb7aa33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adenocarcinoma</topic><topic>Apoptosis</topic><topic>Biomarkers</topic><topic>Breast cancer</topic><topic>CCL19 protein</topic><topic>CCR7 protein</topic><topic>Cholangiocarcinoma</topic><topic>Deoxyribonuclease</topic><topic>Esophagus</topic><topic>Gene expression</topic><topic>Head & neck cancer</topic><topic>Hepatocellular carcinoma</topic><topic>Immune response</topic><topic>Immune system</topic><topic>Immunohistochemistry</topic><topic>Immunotherapy</topic><topic>Infiltration</topic><topic>Invasiveness</topic><topic>Kidneys</topic><topic>Leukemia</topic><topic>Liver</topic><topic>Liver cancer</topic><topic>Lung cancer</topic><topic>Lung carcinoma</topic><topic>Lymphoma</topic><topic>Medical prognosis</topic><topic>Melanoma</topic><topic>Mesothelioma</topic><topic>Metastases</topic><topic>mRNA</topic><topic>Neutrophils</topic><topic>Original Research</topic><topic>Ovarian cancer</topic><topic>Paraffin</topic><topic>Prognosis</topic><topic>Prostate</topic><topic>RNA</topic><topic>Sarcoma</topic><topic>Signal transduction</topic><topic>Skin cancer</topic><topic>Software</topic><topic>Stomach</topic><topic>Thyroid cancer</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Deng, Zenghua</creatorcontrib><creatorcontrib>Xiao, Mengmeng</creatorcontrib><creatorcontrib>Du, Dexiao</creatorcontrib><creatorcontrib>Luo, Nan</creatorcontrib><creatorcontrib>Liu, Dongfang</creatorcontrib><creatorcontrib>Liu, Tingting</creatorcontrib><creatorcontrib>Lian, Dongbo</creatorcontrib><creatorcontrib>Peng, Jirun</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest research library</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>OncoTargets and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Deng, Zenghua</au><au>Xiao, Mengmeng</au><au>Du, Dexiao</au><au>Luo, Nan</au><au>Liu, Dongfang</au><au>Liu, Tingting</au><au>Lian, Dongbo</au><au>Peng, Jirun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>DNASE1L3 as a Prognostic Biomarker Associated with Immune Cell Infiltration in Cancer</atitle><jtitle>OncoTargets and therapy</jtitle><addtitle>Onco Targets Ther</addtitle><date>2021-01-01</date><risdate>2021</risdate><volume>14</volume><spage>2003</spage><epage>2017</epage><pages>2003-2017</pages><issn>1178-6930</issn><eissn>1178-6930</eissn><abstract>Deoxyribonuclease 1 like 3 (DNASE1L3) is critically involved in apoptosis and immune response, however, its role in cancer has yet to be deciphered. We aimed to explore the prognostic value of DNASE1L3 across a series of malignancies.
Based on Oncomine database and Tumor Immune Estimation Resource (TIMER), expression profiling of DNASE1L3 was detailed in malignancies. Using PrognoScan, Kaplan-Meier Plotter, GEPIA2, and bc-GenEcMiner v4.5, prognostic value of DNASE1L3 was estimated in diverse cancers. Based on TIMER, association between DNASEL13 expression and immune infiltration was examined in various cancers. Then, mRNA level of DNASE1L3 in hepatocellular carcinoma (HCC) samples (n=22) and stomach adenocarcinoma (STAD) samples (n=17) was measured with qRT-PCR. Immunohistochemistry was performed to confirm expression of DNASE1L3 in paraffin-embedded tissues of HCC (n=9) and lung adenocarcinoma (n=20).
DNASE1L3 was downregulated in multiple cancers, including breast invasive carcinoma (BRCA), cholangiocarcinoma (CHOL), liver hepatocellular carcinoma (LIHC), and lung adenocarcinoma (LUAD). A lower level of DNASE1L3 correlated with poorer prognosis in various cancers, especially in breast, liver, kidney, stomach, lung adenocarcinoma and sarcoma (SARC). Moreover, DNASE1L3 was positively related to immune cell infiltration in many cancers, including BRCA, LIHC, STAD, LUAD, and SARC. DNASE1L3 was significantly associated with CCR7/CCL19 in cancers. DNASE1L3 was downregulated in HCC and STAD tissues as demonstrated by qRT-PCR, as well as in HCC and LUAD samples, as shown by immunohistochemistry.
DNASE1L3 has potential to serve as a prognostic biomarker in cancer of the breast, kidney, liver, stomach, lung adenocarcinoma and sarcoma. Down-regulation of DNASE1L3 may participate in immune escape via CCR7/CCL19 axis.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>33776450</pmid><doi>10.2147/OTT.S294332</doi><tpages>15</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1178-6930 |
| ispartof | OncoTargets and therapy, 2021-01, Vol.14, p.2003-2017 |
| issn | 1178-6930 1178-6930 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7987320 |
| source | DOVE Medical Press Journals; Taylor & Francis Open Access(OpenAccess); PubMed Central; EZB Electronic Journals Library; PubMed Central Open Access |
| subjects | Adenocarcinoma Apoptosis Biomarkers Breast cancer CCL19 protein CCR7 protein Cholangiocarcinoma Deoxyribonuclease Esophagus Gene expression Head & neck cancer Hepatocellular carcinoma Immune response Immune system Immunohistochemistry Immunotherapy Infiltration Invasiveness Kidneys Leukemia Liver Liver cancer Lung cancer Lung carcinoma Lymphoma Medical prognosis Melanoma Mesothelioma Metastases mRNA Neutrophils Original Research Ovarian cancer Paraffin Prognosis Prostate RNA Sarcoma Signal transduction Skin cancer Software Stomach Thyroid cancer Tumors |
| title | DNASE1L3 as a Prognostic Biomarker Associated with Immune Cell Infiltration in Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T07%3A37%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=DNASE1L3%20as%20a%20Prognostic%20Biomarker%20Associated%20with%20Immune%20Cell%20Infiltration%20in%20Cancer&rft.jtitle=OncoTargets%20and%20therapy&rft.au=Deng,%20Zenghua&rft.date=2021-01-01&rft.volume=14&rft.spage=2003&rft.epage=2017&rft.pages=2003-2017&rft.issn=1178-6930&rft.eissn=1178-6930&rft_id=info:doi/10.2147/OTT.S294332&rft_dat=%3Cgale_pubme%3EA669417984%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2513586642&rft_id=info:pmid/33776450&rft_galeid=A669417984&rfr_iscdi=true |